𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mortality trends for benign prostatic hyperplasia and prostate cancer in English populations 1979–2006

✍ Scribed by Marie E. Duncan; Michael J. Goldacre

Book ID
110923012
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
285 KB
Volume
107
Category
Article
ISSN
1464-4096

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CYP17 polymorphisms in relation to risks
CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: A population-based study in China
✍ M. Patricia Madigan; Yu-Tang Gao; Jie Deng; Ruth M. Pfeiffer; Bao-Li Chang; Siqu 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 78 KB 👁 1 views

## Abstract Because androgens likely play a key role in prostate growth and prostate cancer development, variants of genes involved in androgen biosynthesis may be related to prostate cancer risk. The enzyme P450c17α, encoded by the __CYP17__ gene, catalyzes the conversion of progesterone and pregn

Polymorphisms of fibroblast growth facto
Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population
✍ Zhiyong Ma; Norihiko Tsuchiya; Takeshi Yuasa; Takamitsu Inoue; Teruaki Kumazawa; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 138 KB 👁 1 views

## Abstract Fibroblast growth factor receptor 4 (FGFR4) is a member of a family of transmembrane receptors with ligand‐induced tyrosine kinase activity. The Glycine (Gly) to Arginine (Arg) polymorphism at codon 388 (Gly388Arg), which encodes an amino acid in the transmembrane part of the FGFR4 gene

Incidence and mortality trends for prost
Incidence and mortality trends for prostate cancer in 5 French areas from 1982 to 1996
✍ Emmanuel Chirpaz; Marc Colonna; François Menegoz; Pascale Grosclaude; Paul Schaf 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 122 KB

## Abstract After an increase in the 1980s, incidence and mortality for prostate cancer in North America or England and Wales started to decrease in the early 1990s. The reasons for this evolution are widely debated, notably the importance of early detection. This study describes trends of prostate